Innate Pharma (IPHA) Total Current Liabilities (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Total Current Liabilities data on file, last reported at $42.7 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 21.04% year-over-year to $42.7 million; the trailing twelve-month figure through Dec 2025 stood at $42.7 million (up 21.04% YoY), and the FY2025 full-year result was $42.7 million, up 21.04% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $42.7 million, up from $33.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $91.4 million in Q4 2021 and bottomed at $33.3 million in Q2 2025.
• The 5-year median for Total Current Liabilities is $42.4 million (2022), against an average of $49.9 million.
• Peak annual rise in Total Current Liabilities reached 68.5% in 2021, while the deepest fall reached 99.94% in 2021.
• A 5-year view of Total Current Liabilities shows it stood at $91.4 million in 2021, then sank by 53.85% to $42.2 million in 2022, then grew by 1.12% to $42.6 million in 2023, then slipped by 17.36% to $35.2 million in 2024, then rose by 21.04% to $42.7 million in 2025.
• The last three Total Current Liabilities figures came in at $42.7 million (Q4 2025), $33.3 million (Q2 2025), and $35.2 million (Q4 2024), per Business Quant data.

Peer Comparison